TY - JOUR
T1 - Antibodies Against Laminaribioside and Chitobioside Are Novel Serologic Markers in Crohn's Disease
AU - Dotan, Iris
AU - Fishman, Sigal
AU - Dgani, Yaara
AU - Schwartz, Mikael
AU - Karban, Amir
AU - Lerner, Aaron
AU - Weishauss, Oori
AU - Spector, Larissa
AU - Shtevi, Avi
AU - Altstock, Rom T.
AU - Dotan, Nir
AU - Halpern, Zamir
N1 - Funding Information:
Not supported by award or grant.
PY - 2006/8
Y1 - 2006/8
N2 - Background & Aims: New serologic markers of inflammatory bowel disease may be useful for differentiating between Crohn's disease and ulcerative colitis and for disease stratification. We profiled sugar-binding antibodies to identify novel antiglycan antibodies that may be associated with inflammatory bowel disease. Methods: Serum samples were obtained from patients with diagnosed Crohn's disease or ulcerative colitis and from control patients. The presence of antiglycan antibodies was evaluated using either a glycan array (GlycoChip; Glycominds, Ltd, Lod, Israel) in patients with Crohn's disease (n = 72) or ulcerative colitis (n = 56) and in healthy controls (n = 41) or using an enzyme-linked immunosorbent assay in patients with Crohn's disease (n = 124), ulcerative colitis (n = 106), and in control patients (n = 101). Results: Inaddition to antibodies against mannan, antibodies to laminaribioside (Glc[β1,3]Glc[β]) and chitobioside (GlcNAc[β1,4]GlcNAc[β]) had the highest discriminative capability between Crohn's disease and ulcerative colitis (P < .001 and P < .05, respectively). Importantly, 44% (12/27) of anti-Saccharomyces cerevisiae antibody-negative Crohn's disease patients were positive for antilaminaribioside or antichitobioside. In patients with inflammatory bowel disease positive for antibodies against either laminaribioside, chitobioside, or mannan, the diagnosis of Crohn's disease was suggested with a sensitivity of 77.4% and specificity of 90.6%. Having at least 2 of these antibodies increased the specificity to 99.1%. In Crohn's disease, higher levels of antibodies against laminaribioside or mannan were significantly associated with small intestinal disease (P = .03 and P < .0001, respectively). Conclusions: Antilaminaribioside and antichitobioside carbohydrate antibodies are novel serologic markers associated with Crohn's disease. These antibodies may contribute to the diagnosis and improved stratification of Crohn's disease.
AB - Background & Aims: New serologic markers of inflammatory bowel disease may be useful for differentiating between Crohn's disease and ulcerative colitis and for disease stratification. We profiled sugar-binding antibodies to identify novel antiglycan antibodies that may be associated with inflammatory bowel disease. Methods: Serum samples were obtained from patients with diagnosed Crohn's disease or ulcerative colitis and from control patients. The presence of antiglycan antibodies was evaluated using either a glycan array (GlycoChip; Glycominds, Ltd, Lod, Israel) in patients with Crohn's disease (n = 72) or ulcerative colitis (n = 56) and in healthy controls (n = 41) or using an enzyme-linked immunosorbent assay in patients with Crohn's disease (n = 124), ulcerative colitis (n = 106), and in control patients (n = 101). Results: Inaddition to antibodies against mannan, antibodies to laminaribioside (Glc[β1,3]Glc[β]) and chitobioside (GlcNAc[β1,4]GlcNAc[β]) had the highest discriminative capability between Crohn's disease and ulcerative colitis (P < .001 and P < .05, respectively). Importantly, 44% (12/27) of anti-Saccharomyces cerevisiae antibody-negative Crohn's disease patients were positive for antilaminaribioside or antichitobioside. In patients with inflammatory bowel disease positive for antibodies against either laminaribioside, chitobioside, or mannan, the diagnosis of Crohn's disease was suggested with a sensitivity of 77.4% and specificity of 90.6%. Having at least 2 of these antibodies increased the specificity to 99.1%. In Crohn's disease, higher levels of antibodies against laminaribioside or mannan were significantly associated with small intestinal disease (P = .03 and P < .0001, respectively). Conclusions: Antilaminaribioside and antichitobioside carbohydrate antibodies are novel serologic markers associated with Crohn's disease. These antibodies may contribute to the diagnosis and improved stratification of Crohn's disease.
UR - http://www.scopus.com/inward/record.url?scp=33746542174&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2006.04.030
DO - 10.1053/j.gastro.2006.04.030
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 16890590
AN - SCOPUS:33746542174
SN - 0016-5085
VL - 131
SP - 366
EP - 378
JO - Gastroenterology
JF - Gastroenterology
IS - 2
ER -